๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Equivalent)

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our USA, China, UK, Ireland and India registers that name Equivalent) as an intervention. Synced 24 Sep 2026
6Trials tracked
4Recruiting now
3Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Equivalent) is named as a drug or biological intervention in 6 clinical trials in our USA, China, UK, Ireland and India trial registers, 4 of which are recruiting. Lead sponsors include Merck Sharp & Dohme LLC (4), Sanofi (1) and AstraZeneca (1). Registered phases: Phase 3, Phase 1/2 and Phase 2. Conditions studied include Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.

01

Clinical trials of Equivalent)

6 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 3 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT06788912 Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) (ClinicalTrials.gov ↗)
Lung Neoplasm Malignant
Phase 2 Recruiting Merck Sharp & Dohme LLC USA
NCT05319730 A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Phase 1/2 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06564038 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
Phase 1/2 Recruiting AstraZeneca UK, USA, China
NCT04270409 Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (ClinicalTrials.gov ↗)
Plasma Cell Myeloma
Phase 3 Active, closed Sanofi Ireland, UK, USA, China
NCT06305754 Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (ClinicalTrials.gov ↗)
Non-small Cell Lung Cancer (NSCLC)
Phase 3 Active, closed Merck Sharp & Dohme LLC USA, India, China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

11 conditions
Condition (as registered)Trials
Ovarian Cancer1
Fallopian Tube Cancer1
Primary Peritoneal Cancer1
Plasma Cell Myeloma1
Chronic Lymphocytic Leukaemia1
Small Lymphocytic Lymphoma1
Mantle-cell Lymphoma1
Large B-cell Lymphoma1
Esophageal Squamous Cell Carcinoma1
Non-small Cell Lung Cancer (NSCLC)1
Lung Neoplasm Malignant1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Merck Sharp & Dohme LLC4
Sanofi1
AstraZeneca1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Equivalent) works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Equivalent) (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.